SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community emphasizes its cultural significance and draws comparisons to Bitcoin. The community highlights the coin's focus on culture, freedom, and growth within the cannabis space, with some mentioning a recent token burn and ongoing development efforts.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending as investors discuss the potential of quantum computing stocks following recent government contracts and increased institutional interest. Community members are debating the company's valuation relative to its revenue, with some expressing concerns about a potential pullback, while others remain optimistic about its long-term growth prospects in the quantum computing sector. The conversation also includes comparisons to other quantum computing stocks and discussions around potential short squeezes.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the crypto community anticipates potential ETF approvals and discusses the implications of a government shutdown on the timeline. Community members are focused on XRP's ability to break the $3 resistance level, while also debating its utility and future price potential amid the broader crypto market recovery. Bullish sentiment remains despite concerns about market manipulation and the token's historical price action.

Rezolve AI Plc operates in the mobile commerce industry with its cutting-edge engagement platform powered by artificial intelligence and machine learning. It develops AI-based mobile commerce and engagement solutions, simplifying the purchasing process by providing relevant information and facilitating seamless transactions with a single tap. The company enables retailers, brands, and manufacturers to create dynamic connections with consumers across mobile and desktop devices. Rezolve Ai was founded in 2016 and is headquartered in London, the United Kingdom.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI (RZLV) is trending as investors discuss its potential following recent news and a volatile trading period. Community members are debating the impact of analyst ratings and potential short squeezes, while also highlighting the company's AI technology and partnerships. Some are expressing long-term bullish sentiment, while others remain cautious due to the stock's recent fluctuations and past short reports.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending following news of a strategic partnership with Perplexity, an AI search engine, sparking discussions about AI integration and its potential impact on content discovery. The community is also focused on Rumble's relationship with Tether and potential government cloud contracts given the ties between key figures and the company.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as the crypto community debates its next move, particularly as it tests resistance levels. Bullish sentiment is fueled by institutional adoption narratives, while some traders are wary of a potential pullback. Discussions also revolve around the impact of the government shutdown and potential for new all-time highs.

Coin98 is an all-in-one DeFi Platform that aims to fulfill untapped demand in the industry and become a Gateway bridging TradFi users to any DeFi services on multiple blockchains. It accomplishes this mission through a full suite of products, including Coin98 Wallet, Coin98 Exchange, and Space Gate (cross-chain bridge).  Coin98 Wallet: Allows users to store, send, receive, manage crypto assets and connect to numerous dApps on multiple blockchains. It supports over 20 blockchains such as Ethereum, Binance Smart Chain, Solana, Polygon, Avalanche, Terra, etc on both mobile (iOS & android) and Chrome extension versions.  Coin98 Exchange: A multichain liquidity aggregator that allows users to swap, stake, lend, borrow, earn crypto with the best rates and low slippage.  Space Gate: A cross-chain bridge that enables swapping and transferring values across multiple networks. It supports token swaps between ERC20 tokens, BEP20 tokens, SPL tokens, and more.  The C98 token is the native utility token of the Coin98 platform and will be used to pay services fees, as staking incentives, for governance, and unique membership rights.

Coin98

Coin98 is trending as traders discuss its potential for both significant gains and losses, with community members pointing to ecosystem growth, product upgrades and staking as catalysts. Bullish traders cite strong volume and recent price action surpassing one-month highs, while others warn of potential pullbacks and compare it to other crypto projects. Overall, the conversation revolves around whether Coin98 can break through resistance levels and reach ambitious price targets.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI ($SOUN) is trending due to after-hours trading activity and speculation around potential new contracts, particularly with a major bank. The community is discussing a possible short squeeze, fueled by high short interest and large after-hours purchases. Bullish sentiment is high, with some anticipating a significant price increase and comparing it to other AI stocks.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community spreads the word and asks, "What's UpDog?" This Solana-based meme token, with locked and burned liquidity, aims to bring humor to the crypto space. Active community members are currently celebrating trending alongside various other tokens.

A multi-agent AI platform dissecting human nature’s first principles through iterative survival challenges and data-driven insights. Core dev has access to one of the founding partners of Two Sigma Ventures - the VC company of one of the biggest hedge funds in the world. Plans to raise seed round and scale after building organic foundation. Project devs are from academia space and are trying to bridge the gap between crypto and academia.

CortexZero

CortexZero is trending as a potential "next-gen gem" within the Solana ecosystem, with community members highlighting its potential for a breakout. Conversations revolve around early entry opportunities and rising volume, with many urging others to buy via Phantom Wallet. The project is also generating buzz related to AI and crypto integration.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is IPF the Next Big Market Opportunity for United Therapeutics?

UTHR reports strong TETON-2 results for Tyvaso in IPF, showing lung function gains and eyeing a major new market.

Top Stock Reports for NextEra Energy, U.S. Bancorp and Air Products & Chemicals

NextEra Energy expands its renewable pipeline, U.S. Bancorp builds on earnings momentum, and Air Products eyes growth despite headwinds.

Can MRK's New Drugs Drive Long-Term Growth Amid Looming Keytruda LOE?

Merck eyes new launches like Capvaxive and Winrevair, among others, to drive long-term growth as Keytruda nears loss of exclusivity.

Theravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals

United Therapeutics hit a record high after its Tyvaso study in idiopathic pulmonary fibrosis met key goals and showed broad patient benefits.

H.C. Wainwright on Tuesday raised its price target on MannKind to $11 from $9 and reiterated its buy rating on the shares, following positive late-stage study results from partner United Therapeutics for its Tyvaso Inhalation Solution.The brokerage firm said the positive data removes “a significant overhang” on MannKind shares and supports a re-rating of the stock toward intrinsic value, with added upside from royalties and cash flows tied to Tyvaso.The call comes after United Therapeutics said Tuesday that its phase 3 TETON-2 trial showed nebulized Tyvaso improved lung function in idiopathic pulmonary fibrosis patients versus placebo in a dose-dependent manner, meeting the trial's primary endpoint.&nbsp;Over 52 weeks, patients on Tyvaso saw lung capacity improve by 95.6 milliliters compared with placebo, a result the company said was highly statistically significant.&nbsp;Benefits were observed across patient subgroups, and significant gains were also reported in quality of life and other secondary measures. The treatment was well-tolerated with no new safety signals.United Therapeutics said it plans to meet with the U.S. Food and Drug Administration before the end of the year to discuss adding IPF to Tyvaso’s label, with additional data from the ongoing TETON-1 study expected in the first half of 2026.Last week, MannKind said that United Therapeutics had exercised an option under their 2018 license and collaboration agreement to&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mannkind-united-therapeutics-expand-agreement-to-develop-second-investigational-molecule-together/chsURMTRdkC">develop a second dry powder inhalation therapy</a>. The partnership previously produced Tyvaso DPI, the first FDA-approved dry powder inhalation treatment for pulmonary hypertension, cleared in 2022.MannKind will use its Technosphere platform to formulate a new investigational molecule, while United Therapeutics will conduct preclinical and clinical testing. MannKind will receive $5 million upfront, up to $35 million in milestone payments, and a 10% royalty on sales if the therapy reaches market.&nbsp;On Stocktwits, retail sentiment for both MannKind and United Therapeutics was ‘extremely bullish’ amid ‘extremely high’ message volume.One user speculated that United Therapeutics’ growing ties to MannKind reduce the likelihood of a buyout by another large pharmaceutical company, saying they expect a 13G filing showing a bigger ownership stake.&nbsp;<stembedurl>https://stocktwits.com/Hard2beLong/message/627299899</stembedurl>Another user questioned whether it made more sense for United Therapeutics to continue paying MannKind a 10% royalty stream each year rather than pursue a full acquisition.<stembedurl>https://stocktwits.com/Lazarus2024/message/627294687</stembedurl>While&nbsp;<a href="https://stocktwits.com/symbol/MNKD">MannKind’s stock</a> has declined 10.7% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/UTHR">United Therapeutics’ stock</a> has risen 14.7% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

H.C. Wainwright on Tuesday raised its price target on MannKind (MNKD) to $11 from $9 and reiterated its buy rating on the shares. (Photo credit: Getty Images)

MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results 

United Therapeutics plans to meet with the U.S. FDA before the end of the year to discuss adding idiopathic pulmonary fibrosis to Tyvaso’s label.

Equity

United Therapeutics Corporation (UTHR) announced on Tuesday that its study evaluating the use of nebulized Tyvaso Inhalation Solution for the treatment of idiopathic pulmonary fibrosis (IPF) demonstrated improvement in lung function relative to placebo.The late-stage study enrolled 597 patients across multiple locations, and Tyvaso demonstrated superiority over placebo in terms of the change in absolute forced vital capacity by 95.6 mL from baseline to week 52 in patients with IPF. Absolute forced vital capacity (FVC) is a measurement used to gauge lung health, referring to the total volume of air in liters that a person can forcibly exhale after taking a deep, maximum inhalation.Idiopathic pulmonary fibrosis, or IPF, is a scarring disease of the lungs of an unknown cause. It is characterized by the progressive loss of the ability of the lungs to transfer oxygen into the blood, ultimately resulting in respiratory failure and death. United Therapeutics estimates there are over 100,000 IPF patients in the United States.<a href="https://stocktwits.com/symbol/UTHR">UTHR stock</a> traded nearly 36% higher at the time of writing. On Stocktwits, retail sentiment around the shares jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume soared from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:624/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_02_at_12_13_28_PM_png_dae41f310b.webp" alt="UTHR's Sentiment Meter and Message Volume as of 12:13 p.m. ET on Sept. 2, 2025 | Source: Stocktwits" width="624" height="63"><figcaption>UTHR's Sentiment Meter and Message Volume as of 12:13 p.m. ET on Sept. 2, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that the positive data implies more funding for more studies.<stembedurl>https://stocktwits.com/DonnyDonowitz/message/627212165</stembedurl>Another user expects the stock to close at $450.<stembedurl>https://stocktwits.com/wallstreet63/message/627228569</stembedurl>United Therapeutics <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.unither.com/press-releases/2025/09-02-2025-120037033">intends</a> to use the data from both the study and an ongoing study of nebulized Tyvaso to support a supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) to add IPF to the labeled indications for nebulized Tyvaso. Data from the ongoing study is expected in the first half of 2026, and the company plans to meet with the FDA before the end of the year to discuss ways to expedite the review process once the data is in, the company said.Following the announcement, multiple analysts hiked their price target on UTHR.<ul style="list-style-type:square;"><li>BofA raised its price target to $463 from $314 and kept a ‘Neutral’ rating on the shares. The firm said that the results were “surprisingly positive” and added that it expects $2.5 billion risk-adjusted peak sales for the drug in IPF.&nbsp;</li><li>Jefferies analyst Roger Song raised the firm's price target to $564 from $432 while keeping a ‘Buy’ rating on the shares.</li></ul>UTHR stock is up by 17% this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/bollinger-innovations-stock-plunges-after-announcing-cost-cutting-measures/chv6vkKRdF3">Why Did Bollinger Innovations Stock Plunge 18% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the United Therapeutics Corporation logo is seen displayed on a smartphone. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

This Pharma Stock Soared 36% Today And Drew Price Target Hikes From Wall Street – More Details Inside

The company reported that Tyvaso demonstrated superiority over the placebo in terms of the change in absolute forced vital capacity, increasing by 95.6 mL from baseline to week 52 in patients with idiopathic pulmonary fibrosis in the trial. 

Why Is United Therapeutics (UTHR) Up 11.9% Since Last Earnings Report?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

MannKind Corporation (MNKD) on Wednesday said that it will formulate a dry powder inhalation therapy, and United Therapeutics (UTHR) will conduct preclinical and clinical development under an expanded agreement.The two companies entered into a licence and collaboration agreement in 2018. The agreement led to the US Food and Drug Administration’s approval of Tyvaso DPI in May 2022 and included an option for United Therapeutics to expand the license to include additional active ingredients. Tyvaso DPI was the first FDA-approved dry powder inhalation treatment for pulmonary hypertension.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MNKD">MNKD</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels. Shares of MNKD traded 5% higher in the pre-market session at the time of writing.Meanwhile, retail sentiment around <a href="https://stocktwits.com/symbol/UTHR">UTHR</a> stayed within ‘neutral’ territory, coupled with ‘low’ levels of retail chatter.MannKind CEO Michael Castagna <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/27/3139981/29517/en/MannKind-Announces-Expansion-of-United-Therapeutics-Collaboration-for-Second-Inhaled-Therapy.html">said</a> that this next step in the collaboration between the two companies strengthens the existing partnership and the versatility of its dry powder formulations.The company said that it will receive an upfront payment of $5 million under the expanded agreement. It is also eligible to receive up to $35 million milestone payments and 10% royalties on net sales of resulting products.Formulation and development activities for the new investigational molecule will begin immediately, the company said. It will be formulated using MannKind’s proprietary Technosphere inhalation technology.While MNKD stock is down by 37% this year, UTHR stock is down by 12%.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-recalls-nearly-356000-vehicles-in-us/chsUG1SRdkx">Ford Issues Nearly 356,000 Vehicles Recall In U.S., But Retail Investors Spot Emerging Catalysts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Together

The 2018 agreement between the companies led to US FDA approval of Tyvaso DPI in May 2022 and included an option for United Therapeutics to expand the license to include additional active ingredients. 

Merck's Narrowed 2025 Sales View: What it Means After Q2 Results?

MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected to drive a second-half rebound.

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

United Therapeutics Corp

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

Current Price	$443.44
Prev Close	$438.18
Open	$433.24
Dividend Yield	0.00%
50-Day Moving Average	$350.62
Beta	0.37
Avg. Volume	1.05M
PE Ratio	17.11

52-Week High	$442.01
52-Week Low	$266.98
Market Capitalization	$19.82B
EPS (Annual)	$24.64
Price to Book	2.76
Revenue Per Employee	$2.2M
Enterprise Value/EBITDA	N/A

UTHR
United Therapeutics Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest UTHR News

UTHR United Therapeutics Corp